1-7 of 7
Niall C. Tebbutt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study

Lavinia Tan, Ben Tran, Jeanne Tie, Ben Markman, Sumi Ananda, Niall C. Tebbutt, Michael Michael, Emma Link, Stephen Q. Wong, Sushma Chandrashekar, Jerick Guinto, David Ritchie, Rachel Koldej, Benjamin J. Solomon, Grant A. McArthur, Rodney J. Hicks, Peter Gibbs, Sarah-Jane Dawson, Jayesh Desai
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1017–1030.
https://doi.org/10.1158/1078-0432.CCR-22-3094
Published: 14 March 2023
View article titled, A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in <em>BRAF</em> V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
Open the PDF for A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in <em>BRAF</em> V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study in another window
Includes: Supplementary data
Journal Articles

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Manish A. Shah, Kohei Shitara, Florian Lordick, Yung-Jue Bang, Niall C. Tebbutt, Jean-Phillippe Metges, Kei Muro, Keun-Wook Lee, Lin Shen, Sergei Tjulandin, John L. Hays, Naureen Starling, Rui-Hua Xu, Keren Sturtz, Marilyn Fontaine, Cindy Oh, Emily M. Brooks, Bo Xu, Wei Li, Chiang J. Li, Laura Borodyansky, Eric Van Cutsem
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3686–3694.
https://doi.org/10.1158/1078-0432.CCR-21-4021
Published: 02 September 2022
View article titled, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Open the PDF for Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study

Jennifer Mooi, Fiona Chionh, Peter Savas, Jessica Da Gama Duarte, Geoffrey Chong, Stephen Brown, Rachel Wong, Timothy J. Price, Alysson Wann, Effie Skrinos, John M. Mariadason, Niall C. Tebbutt
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2159–2167.
https://doi.org/10.1158/1078-0432.CCR-20-2714
Published: 15 April 2021
View article titled, Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Open the PDF for Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study in another window
Includes: Supplementary data
Journal Articles

Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer

Geoffrey Liu, Dongsheng Tu, Marcia Lewis, Dangxiao Cheng, Leslie A. Sullivan, Zhuo Chen, Eric Morgen, John Simes, Timothy J. Price, Niall C. Tebbutt, Jeremy D. Shapiro, G. Mark Jeffery, J. Daniel Mellor, Thomas Mikeska, Shakeel Virk, Lois E. Shepherd, Derek J. Jonker, Christopher J. O'Callaghan, John R. Zalcberg, Christos S. Karapetis, Alexander Dobrovic
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (10): 2435–2444.
https://doi.org/10.1158/1078-0432.CCR-15-0414
Published: 12 May 2016
View article titled, Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer
Open the PDF for Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

Eric Van Cutsem, Cathy Eng, Elzbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith Mitchell, Irina Davidenko, Joe Stephenson, Elena Elez, Hans Prenen, Hongjie Deng, Rui Tang, Ian McCaffery, Kelly S. Oliner, Lisa Chen, Jennifer Gansert, Elwyn Loh, Dominic Smethurst, Josep Tabernero
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (16): 4240–4250.
https://doi.org/10.1158/1078-0432.CCR-13-2752
Published: 13 August 2014
View article titled, Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type <em>KRAS</em> Metastatic Colorectal Cancer
Open the PDF for Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type <em>KRAS</em> Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17

Christos S. Karapetis, Derek Jonker, Manijeh Daneshmand, Jennifer E. Hanson, Christopher J. O'Callaghan, Celia Marginean, John R. Zalcberg, John Simes, Malcolm J. Moore, Niall C. Tebbutt, Timothy J. Price, Jeremy D. Shapiro, Nick Pavlakis, Peter Gibbs, Guy A. Van Hazel, Ursula Lee, Rashida Haq, Shakeel Virk, Dongsheng Tu, Ian A.J. Lorimer, for the NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (3): 744–753.
https://doi.org/10.1158/1078-0432.CCR-13-0606
Published: 02 February 2014
View article titled, <em>PIK3CA, BRAF</em>, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17
Open the PDF for <em>PIK3CA, BRAF</em>, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17 in another window
Journal Articles

Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers

Rebecca A. Herbertson, Niall C. Tebbutt, Fook-Thean Lee, David J. MacFarlane, Bridget Chappell, Noel Micallef, Sze-Ting Lee, Timothy Saunder, Wendie Hopkins, Fiona E. Smyth, David K. Wyld, John Bellen, Daryl S. Sonnichsen, Martin W. Brechbiel, Carmel Murone, Andrew M. Scott
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (21): 6709–6715.
https://doi.org/10.1158/1078-0432.CCR-09-0536
Published: 02 November 2009
View article titled, Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers
Open the PDF for Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers in another window